Assessment of an asymmetrical coating stent with sirolimus released from ablumial matrix in porcine model

Clinical Research in Cardiology

Volumn 101, Issue 11, 2012, Pages 917-927

  Shen, Li ^a   Wu, Yizhe ^a   Zhang, Feng ^a   Wu, Lingxiang ^b   Dong, Chao ^b   Gao, Yongxing ^a   Sun, Aijun ^a   Zou, Yunzeng ^a   Qian, Juying ^a   Sun, Jianguo ^c   Zhong, Wei ^c   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b OrbusNeich Medical (Shenzhen) Co Ltd   (China)

^c Shanghai Center for Biomedical Engineering   (China)

Author keywords

Endothelialization; In stent stenosis; Percutaneous coronary intervention

Indexed keywords

ACETYLCHOLINE; RAPAMYCIN;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; FOLLOW UP; INTRAVASCULAR ULTRASOUND; MINIPIG; MORPHOMETRICS; NONHUMAN; SCANNING ELECTRON MICROSCOPY; STENT THROMBOSIS; VASOCONSTRICTION;

ACETYLCHOLINE; ANIMALS; CARDIOVASCULAR AGENTS; CHITOSAN; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; HEPARIN; HYPERPLASIA; METALS; MICROSCOPY, ELECTRON, SCANNING; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; SIROLIMUS; SWINE; SWINE, MINIATURE; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL; VASOCONSTRICTION;

EID: 84869130214     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0476-7     Document Type: Article

References (24)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323
2. Tentzeris I, Jarai R, Farhan S, Wojta J, Schillinger M, Geppert A, Nürnberg M, Unger G, Huber K (2011) Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: A single centre experience. Clin Res Cardiol 100:191-200
3. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE, ENDEAVOR III Investigators (2007) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 48:2440-2447
4. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2:286-294
5. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schömig A, Kastrati A (2012) Everolimuseluting versus sirolimus-eluting stents: An updated meta-analysis of randomized trials. Clin Res Cardiol (Epub ahead of print)
6. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193-202
7. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R (2009) Comparison of inflammatory response after implantation of sirolimus-and paclitaxeleluting stents in porcine coronary arteries. Circulation 120: 141-149
8. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R (2008) Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52:333-342
9. Webster MW, Ormiston JA (2007) Drug-eluting stents and late stent thrombosis. Lancet 370:914-915
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium (2007) Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 115:2344-2351
11. Guagliumi G, Sirbu V, Musumeci G, Bezerra HG, Aprile A, Kyono H, Fiocca L, Matiashvili A, Lortkipanidze N, Vassileva A, Popma JJ, Allocco DJ, Dawkins KD, Valsecchi O, Costa MA (2010) Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical coherence tomography drug-eluting stent investigation (OCTDESI). Circ Cardiovasc Interv 3: 367-375
12. Grube E, Schofer J, Hauptmann KE, Nickenig G, Curzen N, Allocco DJ, Dawkins KD (2010) A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. JACC Cardiovasc Interv 3:431-438
13. Nakazawa G, Granada JF, Alviar CL, Tellez A, Kaluza GL, Guilhermier MY, Parker S, Rowland SM, Kolodgie FD, Leon MB, Virmani R (2010) Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 3:68-75
14. Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-BradleyD, Parker S, Rowland S, Nakazawa G, VorpahlM, Kolodgie FD, Kaluza GL, Leon MB, Virmani R (2010) Development of a novel prohealing stent designed to deliver sirolimus froma biodegradable abluminal matrix. Circ Cardiovasc Interv 3:257-266
15. Meng S, Liu ZJ, Shen L, Guo Z, Chou LL, Zhong W, Du QG, Ge JB (2009) The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 30:2276-2283
16. Brott BC, Anayiotos AS, Charpman GD, Anderson PG, Hillegass WB (2006) Severe, diffuse coronary artery spasm after drugeluting stent placement. J Invasive Cardiol 18:584-592
17. Li J, Jabara R, Pendyala L, Otsuka Y, Shinke T, Hou D, Robinson K, Chronos N (2008) Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. JACC Cardiovasc Interv 1:279-285
18. Fukuda D, Sata M, Tanaka K, Nagri R (2005) Potent inhibitory effect of the sirolimus on the circulating vascular progenitor cells. Circulation 111:926-931
19. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 87:840-844
20. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardines N (2002) Comparative study of cyclosporine vs newer immunosuppressants mycophenalate mofetil and rapamycin on the coronary endothelial function. J Heart Lung Transplant 21:990-998
21. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, Leon MB, Moses JW, Bonneau HN, Fitzgerald PJ (2005) Late incomplete apposition after sirolimus-eluting stent implantation. A serial intravascular ultrasound analysis. J Am Coll Cardiol 46:1002-1005
22. van der Hoeven BL, Liem SS, Dijkstra J, Bergheanu SC, Putter H, Antoni ML, Atsma DE, Bootsma M, Zeppenfeld K, Jukema JW, Schalij MJ (2008) Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: Acute and 9-month intravascular ultrasound results of the MISSION! intervention study. JACC Cardiovasc Interv 1:192-201
23. Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R, Abizaid AA, Tanajura LF, Chaves A, Centemero M, Sousa AG, Sousa JE (2007) Late incomplete apposition after drug-eluting stent implantation: Incidence and potential for adverse clinical outcomes. Eur Heart J 28:1304-1309
24. Lang NN, Newby DE (2007) Emerging thrombotic effects of drug eluting stents. Arterioscler Thromb Vasc Biol 27:261-262